Loading clinical trials...

Incretin Effect in Patients With Psoriasis and Controls | Clinical Trials | Clareo Health

COMPLETED

Incretin Effect in Patients With Psoriasis and Controls

Incretin Effect in Patients With Psoriasis

NCT06064084•University Hospital, Gentofte, Copenhagen

View on ClinicalTrials.gov

Summary

To investigate the incretin effect and postprandial incretin responses in plasma in patients with psoriasis

Eligibility

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•no diabetes BMI \< 27 kg/m\^2 normal Glucose tolerance test at screening normal fasting plasma glucose no islet auto antibodies no hormonel contraception informed consent psoriasis vulgaris (PASI\>8) (case not controls)

Exclusion Criteria

•other chronic inflammtory skin disease other chronic inflammatory disease pregnancy psychiatric illness

Key Dates

Start Date

September 11, 2011

Primary Completion Date

September 11, 2015

Completion Date

September 11, 2015

Last Updated

October 3, 2023

Enrollment

ACTUAL participants

Conditions

Psoriasis Vulgaris

Interventions

Oral glucose tolerance test

DIAGNOSTIC_TEST

Intravenous isoglycaemic glucose clamp

OTHER

Liquid Mixed meal test

OTHER

Therapeutic Drug Monitoring of Brodalumab in Psoriasis Patients (BIOLOPTIM-BRO)

NCT04080635

Psoriasis Vulgaris

View study

COMPLETEDPHASE4

Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis

NCT04340076

PsoriasisPsoriasis Vulgaris

View study

WITHDRAWNNA

Safety and Effectiveness of Combined LED Light for the Treatment of Mild to Moderate Plaque Type Psoriasis Vulgaris

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 3, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Incretin Effect in Patients With Psoriasis and Controls

Inclusion Criteria

Exclusion Criteria

Therapeutic Drug Monitoring of Brodalumab in Psoriasis Patients (BIOLOPTIM-BRO)

Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis

Safety and Effectiveness of Combined LED Light for the Treatment of Mild to Moderate Plaque Type Psoriasis Vulgaris

Special Drug Use-results Survey to Evaluate Safety and Efficacy of Cosentyx in Pediatric Patients With PsV, PsA, or GPP

A Pilot Study to Explore the Role of Gut Flora in Psoriasis

The Mediterranean Diet and Time-Restricted Eating Dietary Interventions for Psoriasis Study